Lung Cancer

Face-Off: Introduction of the Non-Small Lung Cancer (NSCLC) Debate

The outcomes of the use of Sotorasib in patients with pretreated KRAS G12C mutated NSCLC.

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS

Brigatinib Versus Crizotinib in ALK inhibitor-Naïve Advanced ALK-Positive NSCLC: Results of Phase 3 ALTA-1L Trial

Highlight on the debate format, speakers, and direction to support the discussion.

Deborah Doroshow, MD;Neel Chudgar, MD;Vamsidhar Velcheti, MD;Daniel R. Gomez, MD;Jamie E Chaft, MD;Fred R. Hirsch, MD, PhD;Mark G. Kris, MD

Introduction of the Debate Between Jets v. Giants

Results of phase 3 ALTA-1L study comparing crizotinib with Brigatinib in advanced ALK-positive non-small cell lung cancer

Deborah Doroshow, MD;Neel Chudgar, MD;Vamsidhar Velcheti, MD;Daniel R. Gomez, MD;Jamie E Chaft, MD;Fred R. Hirsch, MD, PhD;Mark G. Kris, MD

Optimizing EGFR-Mutant NSCLC Care: Future Directions

An outline of the debate, the speakers, and the basic guidelines to support the program.

The Future of Treatment for NSCLC With EGFR Exon 20 Insertion Mutations

Closing insights into managing EGFR-mutant NSCLC, from evolving treatment options and sequencing strategies to addressing unmet needs and the importance of comprehensive genomic testing.

Misako Nagasaka, MD, PhD;Sai-Hong Ou, MD, PhD;Janellen Smith, MD

Unmet Needs in EGFR Exon 20 Insertion Non–Small Cell Lung Cancer

Dr Sai-Hong Ou discusses the future of treatment for non-small cell lung cancer with EGFR exon 20 insertion mutations, highlighting the complexity of these mutations and the need for precision treatments.

Management Strategies for Adverse Events Seen With Amivantamab in NSCLC With EGFR Exon 20 Insertion Mutations

Unmet needs in EGFR exon 20 insertion lung cancer, emphasizing the importance of early identification, selectivity against wild type EGFR, CNS activity, and mechanisms of resistance.

Misako Nagasaka, MD, PhD;Sai-Hong Ou, MD, PhD;Janellen Smith, MD

BI 764532 Earns FDA FTD in Large Cell Lung Neuroendocrine Carcinoma

Drs Misako Nagasaka, Sai-Hong Ou, Janellen Smith discuss the management of adverse events, such as infusion reactions and rash, associated with amivantamab treatment for patients with EGFR exon 20 insertion mutations.

Investigators are assessing BI 764532 in extensive-stage small cell lung cancer and other neuroendocrine carcinoma as part of the phase 2 DAREON-5 study.

Russ Conroy

November 29th 2023

Investigators are assessing BI 764532 in extensive-stage small cell lung cancer and other neuroendocrine carcinoma as part of the phase 2 DAREON-5 study.

EGFR Exon 20 Insertion NSCLC: A Comprehensive Overview

Patient Case Presentation: A 69-Year-Old Man With NSCLC With EGFR Exon 20 Insertion Mutations

Experts discuss the rapidly evolving treatment landscape for EGFR exon 20 insertion lung cancer, highlighting recent advancements in therapies, clinical trial results, and the quest for first-line treatment options, providing valuable insights into managing this unique patient population.

Misako Nagasaka, MD, PhD;Sai-Hong Ou, MD, PhD;Janellen Smith, MD

Approaches to Managing Patients With EGFR-Mutant NSCLC and EGFR TKI Resistance

Sai-Hong Ou, MD, PhD, and Janellen Smith, MD, discuss the management of a patient with non-small cell lung cancer and an EGFR exon 20 insertion mutation who experienced a rash while on treatment with amivantamab; they highlight the importance of continuous treatment and potential considerations for this patient group.

Misako Nagasaka, MD, PhD;Sai-Hong Ou, MD, PhD;Janellen Smith, MD

Advancements in EGFR-Mutant NSCLC: ADCs and Other Targeted Therapies

Sai-Hong Ou, MD, PhD, discusses the challenging management of patients EGFR-mutant non-small cell lung cancer who develop resistance to EGFR tyrosine kinase inhibitors, emphasizing the importance of understanding the resistance mechanism to tailor treatment.

Common Adverse Events Seen With EGFR TKIs in EGFR-Mutant NSCLC

Learn about the latest developments in the treatment of lung cancer, focusing on EGFR mutations, antibody-drug conjugates (ADCs), targeted therapies, and biomarker-driven approaches to improve patient outcomes in various stages of the disease.

Misako Nagasaka, MD, PhD;Sai-Hong Ou, MD, PhD;Janellen Smith, MD

EGFR-Mutant NSCLC: Second-Line Treatment Options and Safety Data

Drs Janellen Smith and Misako Nagasaka discuss dermatological adverse events in patients with non-small cell lung cancer associated with EGFR tyrosine kinase inhibitors, offering advice on prevention, treatment, and when to involve a dermatologist.

Treatment Approaches for Patients With EGFR-Mutant NSCLC

Shared insight into the complexities in treating EGFR mutant lung cancer during the second-line therapy phase, including safety profiles of different treatment regimens, managing toxicities, and ongoing research to improve patient outcomes.

Misako Nagasaka, MD, PhD;Sai-Hong Ou, MD, PhD;Janellen Smith, MD

Impact of Combination Therapies and CNS Efficacy in EGFR-Mutant NSCLC Treatment

Dr Sai-Hong Ou and Dr Misako Nagasaka discuss the treatment strategies for EGFR-mutant non-small cell lung cancer, emphasizing the importance of individualized decision making and a multidisciplinary approach.

Revolutionizing First-Line Strategies in EGFR-Mutant NSCLC: Combination Therapies

Experts consider the influence of combination therapies on EGFR-mutant lung cancer treatment, including the impact on central nervous system (CNS) response, challenges in CNS metastases management, and the potential alternatives to whole-brain radiation.